Special Issue

Nanoparticle-Based Delivery Systems for Vaccines

Message from the Guest Editor

Developing advanced vaccines is crucial for effectively combating human and animal diseases and improving global well-being. Nanotechnology has significantly enhanced vaccine design, resulting in innovative approaches such as virus-like particle (VLP)-based vaccines, RNA vaccines, and new adjuvants that boost vaccine efficacy. This Special Issue aims to include advancements in vaccine efficacy achieved through nanomaterials to deliver protective antigens. It will also examine vaccine antigens with advantages such as easy purification and high immunogenicity. Additionally, the issue will explore nanomaterials used for alternative routes of administration, particularly those for mucosal vaccines, which hold promise for achieving protective immunity against various diseases. Furthermore, nanoparticles with immunostimulatory properties that can serve as vaccine adjuvants are also interesting. We encourage original research articles and reviews covering research areas that may include antigen delivery using nanomaterials, nano-adjuvants, innovative vaccine antigens, and multifunctional nanoparticles. We look forward to receiving your contributions.

Guest Editor

Dr. Sergio Rosales-Mendoza

Biotechnology Section, Center for Research in Health Science and Biomedicine, Autonomous University of San Luis Potosí, Av. Sierra Leona 550, Lomas de San Luis, San Luis Potosí 78210, Mexico

Deadline for manuscript submissions

31 January 2027

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/216089

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI